PMC:7600245 / 31503-31788
Annnotations
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T117","span":{"begin":44,"end":52},"obj":"Disease"}],"attributes":[{"id":"A117","pred":"mondo_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Moreover, a randomized, open-label trial in COVID-19 adults (n = 127) with mild to moderate symptoms in Hong Kong suggested that adding ribavirin and INF-β-1b to lopinavir/ritonavir increased the efficacy of the treatment when it was initiated within 7 days of the symptoms onset [59]."}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T286","span":{"begin":10,"end":11},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T287","span":{"begin":29,"end":34},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T288","span":{"begin":157,"end":158},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"Moreover, a randomized, open-label trial in COVID-19 adults (n = 127) with mild to moderate symptoms in Hong Kong suggested that adding ribavirin and INF-β-1b to lopinavir/ritonavir increased the efficacy of the treatment when it was initiated within 7 days of the symptoms onset [59]."}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T457","span":{"begin":29,"end":34},"obj":"Chemical"},{"id":"T458","span":{"begin":136,"end":145},"obj":"Chemical"},{"id":"T459","span":{"begin":150,"end":153},"obj":"Chemical"},{"id":"T460","span":{"begin":162,"end":181},"obj":"Chemical"},{"id":"T461","span":{"begin":162,"end":171},"obj":"Chemical"},{"id":"T462","span":{"begin":172,"end":181},"obj":"Chemical"}],"attributes":[{"id":"A457","pred":"chebi_id","subj":"T457","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A458","pred":"chebi_id","subj":"T458","obj":"http://purl.obolibrary.org/obo/CHEBI_63580"},{"id":"A459","pred":"chebi_id","subj":"T459","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A460","pred":"chebi_id","subj":"T460","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A461","pred":"chebi_id","subj":"T461","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A462","pred":"chebi_id","subj":"T462","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"Moreover, a randomized, open-label trial in COVID-19 adults (n = 127) with mild to moderate symptoms in Hong Kong suggested that adding ribavirin and INF-β-1b to lopinavir/ritonavir increased the efficacy of the treatment when it was initiated within 7 days of the symptoms onset [59]."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T230","span":{"begin":0,"end":285},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Moreover, a randomized, open-label trial in COVID-19 adults (n = 127) with mild to moderate symptoms in Hong Kong suggested that adding ribavirin and INF-β-1b to lopinavir/ritonavir increased the efficacy of the treatment when it was initiated within 7 days of the symptoms onset [59]."}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"894","span":{"begin":154,"end":158},"obj":"Gene"},{"id":"908","span":{"begin":136,"end":145},"obj":"Chemical"},{"id":"909","span":{"begin":162,"end":181},"obj":"Chemical"},{"id":"919","span":{"begin":44,"end":52},"obj":"Disease"}],"attributes":[{"id":"A894","pred":"tao:has_database_id","subj":"894","obj":"Gene:1"},{"id":"A908","pred":"tao:has_database_id","subj":"908","obj":"MESH:D012254"},{"id":"A909","pred":"tao:has_database_id","subj":"909","obj":"MESH:C558899"},{"id":"A919","pred":"tao:has_database_id","subj":"919","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Moreover, a randomized, open-label trial in COVID-19 adults (n = 127) with mild to moderate symptoms in Hong Kong suggested that adding ribavirin and INF-β-1b to lopinavir/ritonavir increased the efficacy of the treatment when it was initiated within 7 days of the symptoms onset [59]."}